Compare RYAM & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RYAM | ESPR |
|---|---|---|
| Founded | 1926 | 2008 |
| Country | United States | United States |
| Employees | 2325 | N/A |
| Industry | Paper | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 661.8M | 731.9M |
| IPO Year | 2014 | 2013 |
| Metric | RYAM | ESPR |
|---|---|---|
| Price | $8.73 | $3.13 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $14.00 | $8.75 |
| AVG Volume (30 Days) | 907.6K | ★ 16.9M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 60.71 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,466,397,000.00 | $403,135,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.22 | $12.81 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 21.31 |
| 52 Week Low | $3.35 | $0.79 |
| 52 Week High | $11.85 | $4.18 |
| Indicator | RYAM | ESPR |
|---|---|---|
| Relative Strength Index (RSI) | 41.88 | 70.22 |
| Support Level | $8.15 | $3.11 |
| Resistance Level | $8.80 | $3.18 |
| Average True Range (ATR) | 0.44 | 0.02 |
| MACD | -0.05 | 0.01 |
| Stochastic Oscillator | 23.37 | 21.43 |
Rayonier Advanced Materials Inc engaged in the production and sale of high-purity cellulose and other cellulose-based materials derived from renewable wood fiber. The company operates through five segments: Cellulose Specialties, which produces purified cellulose used in products such as filters, pharmaceuticals, food additives and electronics; Biomaterials, which produces products including biofuels, lignosulfonates and other bio-based chemicals; Cellulose Commodities, which manufactures absorbent and viscose pulp used in textiles and hygiene products; Paperboard, which produces coated paperboard used for packaging and printing applications; and High-Yield Pulp, which produces pulp used in paperboard, packaging and printing paper products.
Esperion Therapeutics Inc is a commercial-stage biopharmaceutical company currently focused on bringing new medicines to patients that address unmet medical needs. It has developed and is commercializing U.S. Food and Drug Administration, or FDA, approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (or CVD and are struggling with elevated low-density lipoprotein cholesterol, or LDL-C. The Company views its operations and manages its business in one operating segment, which is the business of researching, developing, and commercializing therapies for the treatment of patients with elevated LDL-C. The company depends almost entirely on the success of two products, the bempedoic acid tablet and the bempedoic acid/ezetimibe combination tablet.